质量水平
检测方案
≥98% (HPLC)
形式
powder
旋光性
[α]/D -28 to -36° (C= 1.0g/100 ml in CDCl3)
颜色
white to beige
溶解性
DMSO: 2 mg/mL, clear
储存温度
-10 to -25°C
生化/生理作用
Orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus.
Levonorgestrel (D-Norgestrel) is an orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus. Levonorgestrel inhibits the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). D(−)-Norgestrel prevents fertilization by altering cervical mucus consistency, and interfering with the endometrial lining, making it less receptive to implantation. Levonorgestrel (LNG) can be used alone or in combination with estrogen during hormone replacement therapy.
Levonorgestrel (D-Norgestrel) is an orally bioavailable synthetic progestational agent that reversibly binds to progesterone receptors with high-affinity in the hypothalamus, pituitary gland, and uterus. Levonorgestrel inhibits the release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). D(−)-Norgestrel prevents fertilization by altering cervical mucus consistency, and interfering with the endometrial lining, making it less receptive to implantation. Levonorgestrel (LNG) can be used alone or in combination with estrogen during hormone replacement therapy.
警示用语:
Danger
危险声明
危险分类
Carc. 2 - Lact. - Repr. 1A
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Contraception, 54(2), 59-69 (1996-08-01)
The concept of bioavailability is discussed with particular references to the sex steroids. Problems encountered in the measurement of bioavailability of these steroids and the various factors that may affect their bioavailability are briefly described. Information regarding the bioavailability of
American journal of obstetrics and gynecology, 203(6), 547-547 (2010-10-12)
To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system. Searches were conducted on Medline, Embase, Cochrane Library, and Web of Science, and reference lists of relevant
Lancet (London, England), 402(10405), 851-858 (2023-08-20)
Levonorgestrel, a standard drug for emergency contraception (EC), is not effective if administered post-ovulation. A cyclo-oxygenase inhibitor could contribute synergistic effects. We investigated whether a single 40 mg oral dose of piroxicam as co-treatment with levonorgestrel improved emergency contraceptive efficacy.
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门